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Abstract
Background: Approximately 5.3 million Americans, aged 18 and over, carry a diagnosis of
diabetic retinopathy (DR). By the year 2050 this number is expected to triple without effective
healthcare intervention. Approximately 4.8% of the global blindness is attributable to DR, a
silent, progressive, microvascular complication of diabetes. Best practice dictates immediate
screening at time of diagnosis of Type II Diabetes Mellitus (T2DM) and biennial screenings
thereafter, yet this need is often unmet.
Purpose: This study is a continuation of a process put into place by Dr. Michelle Campbell in
October 2017 at the Norton Community Medical Associates Mount Washington practice and was
to determine effectiveness of this intervention. This intervention involved formal referral with a
specific form documenting the results of the ophthalmological screening being faxed back to the
primary care office and scanned into the patient’s electronic health record (EHR).
Methods: This study used a retrospective chart review for the period 1 January 2017 to 1 May
2017 and 1 January 2018 to 1 May 2018 to determine the number of formal referrals to
ophthalmology pre- and post-implementation as well as the number of formal documentation
forms received during both time periods.

Inclusion criteria included T2DM, ICD-10 codes

E11.0-E11.9, and ages between 18 years and 70 years. One hundred charts were selected by the
Information Technology Department for both pre- and post-implementation review.
Results: SPSS Software was used to analyze the data. A chi square test was used to measure
these results. Pre- and post-implementation referrals yielded a p-value of 0.321 which was not
statistically significant; however, pre- and post-implementation documentation yielded a p-value
of .016 which was significant, unfortunately in the opposite direction than was hoped.
Keywords: Diabetic Retinopathy (DR), Electronic Health Record (EHR), Type II Diabetes
Mellitus (T2DM)

Introduction
DR is the most prevalent cause of blindness world-wide. Interestingly, if found early
enough, there are treatments available to prevent blindness. However, this needed screening is
often not obtained in the T2DM population, whether due to the challenge of going to different
facilities for appointments, the lack of knowledge that this is a serious, microvascular
complication of diabetes that is often painless and asymptomatic until too late, or because the
patient just has too much other information to digest and control. Unfortunately, the reasoning
remains unclear as to why screenings are not more consistent in this population. The purpose of
this project was to review the rates of referral for retinopathy screening prior to the
implementation of a formal referral and a formal documentation process to capture these
important screenings in patient’s electronic medical records.
Background
In the United States, there are approximately 5.3 million persons, aged 18 and over, with
a diagnosis of DR (CDC, 2015). This disease is caused by elevated blood glucose levels which
cause damage to the tiny blood vessels in the retina of the eye (Weiss et al., 2015). DR is
specifically a microvascular complication of diabetes that is exacerbated by hypertension in the
uncontrolled diabetic (Molinaro and Dauscher, 2017). By the year 2050 it is anticipated that this
number will triple (Zangalli et al., 2016) without effective healthcare intervention. Global health
spending in 2015 to treat and prevent T2DM complications were somewhere between $673
billion and $1.2 billion (Adil, Siddiqui, Waghdhare, Bhargava & Jha, 2017). Comparatively, in
2004 alone, more than $500 million was spent on healthcare costs, both direct and indirect,
related to blindness and complications caused by DR (Weiss et al., 2015); an increase of
approximately $173 million in eleven years-time. Americans aged 20 to 74 with a new-onset of
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blindness (Weiss et al, 2015) due to DR is expected to create a substantial and costly burden to
healthcare (Zangalli et al, 2016). Interestingly, DR screening and treatment are reportedly highly
cost-effective from a healthcare payer and societal view (Kreft, McGuinness, Doblhammer, &
Finger, 2018).
Diabetic patients have increased risk for visual loss related to cataracts and glaucoma,
retinopathy and correctable visual impairments (McCulloch, 2018). Fraser & D’Amico (2018)
report that DR causes the most impaired vision and is the principal cause of blindness
worldwide. Retinopathy affects 63% of all diabetics and increases the risk of blindness 25 times
greater than non-diabetics (Jimenez-Baez, Marquez-Gonzalez, Barcenas-Contreras, MoralesMontoya & Espinosa-Garcia, 2015). Regular screenings and early treatment are imperative to
preventing progression of DR into blindness in this population. Prevention through good
glycemic control is but one avenue of prevention, although this is no guarantee that DR will not
develop and certainly does not preclude one from recommended screenings (Fraser & D’Amico,
2018). Prompt treatment is imperative for existing disease to preserve vision (Fraser &
D’Amico, 2018).
Unfortunately, the longer a person is diabetic, the higher the incidence of DR (Fraser &
D’Amico, 2018). A meta-analysis of 35 studies conducted worldwide from 1980-2008 revealed
DR exists in 35.4% of diabetic patients globally, and that proliferative DR exists in 7.5% of the
global diabetic population (Solomon, et al., 2017). In developed countries, the leading cause of
new onset blindness in adults aged 20-74 is DR (Solomon, et al., 2017).
Up to one-fifth of patients first diagnosed with T2DM already have signs of DR, and
should, obtain their first screening at the time of diagnosis (Solomon et al, 2017). Thereafter,
3

annual exams are encouraged. However, for the sake of cost-effectiveness, bi-annual exams may
be encouraged for the well-controlled T2DM who has had a normal retinal examination
(Solomon, et al., 2017).
Ninety eight percent of visual loss is preventable with regular follow up, early detection
and treatment. Since proliferative DR and macular edema are painless, leaving the patient oftentimes asymptomatic, it is imperative to provide this population with regular examinations and
subsequent treatment. This only re-iterates the importance of Primary Care Providers referring
these patients for examination and treatment. Solomon et al. (2017) stress the importance of
documenting these examinations in the patient’s electronic health record in the Primary Care
Provider’s office. This necessitates closed loop communication between the Primary Care
Provider and the Ophthalmologist performing the DR screenings and or treatments.
In October 2017 a formal referral protocol was implemented at Norton Community
Medical Associates (NCMA) in Mount Washington, KY to increase retinopathy screening and
documentation rates among patients with T2DM (Campbell, 2017). A referral form was
developed to fax to the optometrist or ophthalmologist with a request to fax the completed form
back to the primary care provider upon completion of the patient’s visit. The completed form
included retinal examination findings and recommendations for follow-up. A 4-week follow-up
evaluation showed no statistically significant difference in referral and documentation rates from
pre- to post-protocol implementation. However, providers in the clinic found the process helpful
and have continued to use the referral protocol.
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Purpose
The overall objective of this project was to evaluate the referral process implemented at
NCMA Mount Washington, KY to increase DR screening and documentation rates among
patients diagnosed with T2DM. More specifically, this project focused on the following
objectives:
1. Compare the rate of referrals for DR screening from pre-implementation to postimplementation years of the referral protocol.
2. Compare documentation rates of DR screening exams from years pre-implementation to
post-implementation of the referral protocol.
Methods
Design. A retrospective chart review was used to evaluate the referral process for DR
screening and formal documentation at NCMA Mount Washington, KY.
Sample. Inclusion criteria were ages 18 to 70 years old with a diagnosis of T2DM,
(ICD-10 codes E-11 to E-11.9) who were seen at the NCMA Mount Washington, KY Clinic.
Exclusion criteria were ages younger than 18 and older than 70 years old and without a diagnosis
of diabetes. There were no exclusions for sex/gender or racial/ethnic groups. For the preimplementation phase a random sample of the electronic health records of 100 patients who met
the inclusion criteria and were seen between January 1, 2017 and May 1, 2017 at the NCMA
Mount Washington Clinic were reviewed. For the post-implementation phase a random sample
of the electronic health records of 100 patients who met the inclusion criteria and were seen
between January 1, 2018 and May 1, 2018 at the NCMA Mount Washington Clinic were
reviewed.
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Informed Consent. Informed consent was waived for this project since it was a
retrospective chart review that presented no more than minimal risk to the participants.
Procedure. The Norton Healthcare Information Technology Department was provided
with inclusion and exclusion criteria. The department used the inclusion and exclusion criteria to
randomly select 100 medical records from the pre-implementation phase and 100 medical
records from the post-implementation phase. These charts were reviewed for formal referral
documentation for DR screenings along with formal documentation of the result of screenings.
Ninety-one charts were included in the pre-implementation review, and 96 charts were included
in the post-implementation review. Nine patient records in the pre-implementation period and 4
patient records in the post implementation period were excluded either by death of the patient or
age criteria. The medical record numbers of each patient were given a unique study ID number
and placed in a crosswalk table. The data contained in the crosswalk table and the spreadsheet
were stored in separate files on the principal investigator’s identity-authenticated secure H-drive,
in a firewall-protected electronic research folder at Norton Healthcare (NHC) that is only
accessible to the principal investigator, NHC Information Services representative(s) and NHC
UK College of Nursing Academic Partnership network administrators trained to establish file
folder access. Demographics collected for this study were age, sex, race, and HgbA1C.
Data Analysis. Data analysis was accomplished using SPSS software and the crosswalk
table. The mean age, and HgbA1C levels were calculated. The race and sex of the individuals
was tallied. A chi-square test was used to determine the rates of referral and formal
documentation for both the pre- and post-implementation reviews.
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Results
Sample Characteristics The demographics of the randomly selected charts included in
the pre-implementation phase are displayed in Table 1. The majority of patients pre- and postimplementation were Caucasian. The difference between male and female pre- and postimplementation were similar, with 92 male and 95 females included. The mean age of patients
randomly selected for this study were 54.6 years-old pre-implementation and 55.2 years-old
post-implementation. The average HbgA1C level was 7.6 pre-implementation and 7.9 postimplementation.
Documentation of Screening and Referrals. The number of patients receiving formal
referral for DR screening were 19 pre- (2017) and 26 post- (2018) implementation (p=.321).
While some improvement was shown, it was not statistically significant. The number of patients
having formal documentation of screening were 16 pre-implementation (2017), and six postimplementation (2018) (p=.016). This is statistically significant; however, in the wrong direction
from what was hoped (see Table 2). This also brings to light the possible lack of closed loop
communication between primary care providers and ophthalmologists providing DR screenings.
Further, it should be noted that providers stand to gain anywhere from $37.50 to $75.00
per formally documented retinopathy screening (Blue Cross and Blue Shield, 2017; Centers for
Medicare and Medicaid Services (2015). This study alone shows only a small portion of the
diabetic community in this one practice. Of the 187 patients who should have received
screening, only 32 (33.4%) total in the pre- and post-implementation phases generated revenue
back to the provider. More importantly, these 32 patients received benefit of screening and
preserving their eyesight a little longer.
7

Discussion
It appears the providers in the study clinic are discussing the need for DR screening in
this population as evidenced by Norton Healthcare’s Best Practice Screening Reminder for the
providers, as most indicated DR was discussed with the patient; however, the use of formal
referral and formal documentation of examination results are sporadic. This data was not the
focus of this study and was therefore, not collected, although it was a part of the review process.
Some formal documentation is present in some patient’s EHR, but documentation is far from
complete.
It is possible that there are those patients who seek eyecare from outside the Norton
Healthcare system or whose insurance does not require referral. It is also possible there are those
that do not seek out the screening, despite being told the necessity by providers. Adil, Siddiqui,
Waghdhare, Bhargava, & Jha (2017) report that many of the respondents in their study did not
receive DR screening and denied knowledge of the importance in relation to their eyesight.
Likewise, Pasqual et al., (2015) report the results of their study found that there is a high noncompliance rate of DR screening among the T2DM population.
Limitations. This study was short-in-duration and did not capture a full year of data.
Perhaps a longer study period would capture more of this population receiving formal referral
and formal documentation for DR screenings. Since these patients are screened every 3 months
by the provider when they are considered uncontrolled diabetics, and every 6 months when they
are considered controlled diabetics, it is possible that a lot of these individuals did not fall within
the study period.
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Implications for Clinical Practice. With the American Diabetes Association (ADA)
guidelines suggesting regular screening for this population, it is imperative that providers strive
to ensure these patients receive the care needed to prevent blindness. Providers coordinate care
for these patients on a regular basis and need to ensure the patient understands the importance of
regular eye examinations. In addition to formal referral for ophthalmologic retinopathy
screening, perhaps the appointment could be confirmed while the patient is still in the office to
ensure the patient is aware of the appointment, and is amenable to it, as well as stressing the
importance of following through with the appointment. In addition, the patient could return a
formal copy of the retinopathy screening for inclusion in their medical records.
Implications for Further Study. Barriers to receiving an ophthalmological screening in
the T2DM population should be explored. The barriers foreseen are transportation, time, and the
difficulties of attending so many appointments in these patients. While providers cannot make a
patient obtain a DR screening, they certainly can assist in addressing any barriers that may exist.
Perhaps an automated system to follow up on receipt of formal documentation could be
implemented within the EPIC system to ensure reminders to both the provider and the
ophthalmologist are generated, increasing the likelihood of receipt of formal documentation.
Conclusion
While providers are aware of the necessity to screen the T2DM population regularly to
provide prompt treatment preventing blindness, there still appears to be a deficit among this
sample in receiving screenings and having formal documentation added to their medical records.
Whatever the issue, it behooves the primary care provider to encourage patients to obtain
screenings to prevent blindness and assist in any way possible to alleviate barriers to care.
9

Table 1. Demographics of Study Population

Age, mean (SD)
HGA1C
Gender, no. (%)
Male
Female
Race, n (%)
Caucasian
American Indian
Asian
African American
Other
Hispanic

Pre-implementation (n =
91)
54.6 (9.6)
7.6

Post-implementation (n
= 96)
55.2 (8.6)
7.9

39 (42.9%)
52 (57.1%)

53 (55.2%)
43 (44.8%)

86 (94.5%)
1 (1.1%)
1 (1.1%)
2 (2.2%)
1 (1.1%)
0 (0.0%)

94 (97.9%)
0 (0.0%)
1 (1.0%)
0 (0.0%)
0 (0.0%)
1 (1.0%)
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p
1.008
.874

Table 2. Diabetic Retinopathy Referrals and Formal Documentation Rates

Referral to ophthalmology
Yes
No
Documentation of screening
Yes
No

Pre-implementation
(n =91)

Post-implementation
(n =96)

p

19 (20.9%)
72 (79.1%)

26 (27.1%)
70 (49.3%)

.321

16 (17.6%)
75 (82.4%)

6 (6.3%)
90 (93.8%)

.016
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